{"filing":{"accession_number":"0001193125-26-352370","cik":"0000944809","ticker":"OPK","company_name":"OPKO HEALTH, INC.","form":"8-K","filing_date":"2026-08-14","report_date":"2026-08-13","primary_document":"opk-20260813.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/944809/000119312526352370/opk-20260813.htm"},"events":[{"id":27951,"run_id":25528,"accession_number":"0001193125-26-352370","anchor_item_number":"1.01","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"OPKO Health entered into an amendment to its Note Purchase Agreement on August 13, 2026, issuing $125 million in aggregate principal amount of senior secured notes maturing in 2044 at SOFR plus 7.5% per annum, secured by royalty interests in mazdutide and Pfizer profit-share payments.","company_name":"OPKO HEALTH, INC.","ticker":"OPK","filing_date":"2026-08-14","form":"8-K","submitted_at":null,"items":[{"id":29683,"accession_number":"0001193125-26-352370","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"OPKO Health entered into an amendment to its Note Purchase Agreement on August 13, 2026, issuing additional senior secured notes with an aggregate principal amount of $125 million, maturing in 2044 and bearing interest at SOFR plus 7.5% per annum. This is a material creation of a new direct financial obligation secured by royalty interests in mazdutide and Pfizer profit-share payments, representing a significant debt issuance that would materially affect investor assessment of the company's capital structure and financial obligations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T20:35:15.063642+00:00","company_name":"","ticker":null,"filing_date":""},{"id":29684,"accession_number":"0001193125-26-352370","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Item 2.03 is the dedicated disclosure item for creation of direct financial obligations, typically debt issuances. The filing incorporates Item 1.01 by reference, which covers material agreements and contracts. This structure is standard for debt offerings and indicates a new financial obligation has been created. Without access to Item 1.01 details, the Item 2.03 heading itself strongly signals a debt issuance or similar direct financial obligation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T20:35:15.063642+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29683,"accession_number":"0001193125-26-352370","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"OPKO Health entered into an amendment to its Note Purchase Agreement on August 13, 2026, issuing additional senior secured notes with an aggregate principal amount of $125 million, maturing in 2044 and bearing interest at SOFR plus 7.5% per annum. This is a material creation of a new direct financial obligation secured by royalty interests in mazdutide and Pfizer profit-share payments, representing a significant debt issuance that would materially affect investor assessment of the company's capital structure and financial obligations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T20:35:15.063642+00:00","company_name":"OPKO HEALTH, INC.","ticker":"OPK","filing_date":"2026-08-14"},{"id":29684,"accession_number":"0001193125-26-352370","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Item 2.03 is the dedicated disclosure item for creation of direct financial obligations, typically debt issuances. The filing incorporates Item 1.01 by reference, which covers material agreements and contracts. This structure is standard for debt offerings and indicates a new financial obligation has been created. Without access to Item 1.01 details, the Item 2.03 heading itself strongly signals a debt issuance or similar direct financial obligation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T20:35:15.063642+00:00","company_name":"OPKO HEALTH, INC.","ticker":"OPK","filing_date":"2026-08-14"}]}